Fundz

Exegenesis Bio and Modalis Enter Partnership to Develop MDL-201 for Duchenne Muscular Dystrophy.

Sep 11, 2026

Contract Type

partnership

PhiladelphiaBiotechnologyHealth CareGeneticsTherapeutics

Description

Exegenesis Bio and Modalis Therapeutics Corporation have signed a research collaboration and license agreement to advance MDL-201, a therapy for Duchenne muscular dystrophy. This partnership leverages Modalis' CRISPR technology and Exegenesis Bio's engineered AAV capsid to enhance research and development efforts.

Company Information

Company

Exegenesis Bio

Location

Philadelphia, Pennsylvania, United States

About

Exegenesis Bio is a clinical stage global gene therapy company focused on developing innovative treatments for rare diseases. Their flagship product, EXG110, aims to treat Fabry disease through a novel gene therapy approach. The company emphasizes its commitment to rigorous science and innovation in the field of gene therapy. Exegenesis Bio is also working on additional therapies targeting other conditions, such as wet Age-Related Macular Degeneration.

Related People

Mahen
Likely contact at this company
••••••••@••••••••

See Mahen's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Exegenesis Bio's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Exegenesis Bio signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.